The function of fibrinogen assay kit

The core function of the fibrinogen assay kit is to quantitatively detect the concentration of plasminogen (Plg) in human serum or plasma in vitro, providing key indicators for clinical diagnosis, treatment monitoring, and scientific analysis. Its specific functions can be carried out from the following three aspects:

1. Clinical diagnosis: Distinguishing the risk of bleeding and thrombosis

Fibrinogen is the core component of the fibrinolytic system, and its abnormal concentration is related to various diseases:

Hypofibrinolysinemia: Decreased concentration may indicate congenital fibrinolysis defects or acquired depletion (such as disseminated intravascular coagulation DIC), leading to bleeding tendency.

Hyperfibrinolysinemia: Elevated concentration may reflect increased fibrinolytic activity, increasing the risk of thrombosis (such as deep vein thrombosis).

. Liver disease monitoring: The liver is the main site of fibrinogen synthesis, and its concentration often significantly decreases in patients with liver disease (such as cirrhosis), which can be used as an auxiliary indicator for liver function assessment.

2. Treatment Monitoring: Guidance for Thrombolysis and Anti Fibrinolysis Therapy

In thrombolytic therapy (such as urokinase, streptokinase) or anti fibrinolytic therapy (such as tranexamic acid), the reagent kit can dynamically monitor fibrinogen levels:

Thrombolysis therapy: basal concentration is measured before treatment, and consumption is monitored during treatment to avoid excessive fibrinolysis leading to bleeding.

.

Anti fibrinolytic therapy: Evaluate drug efficacy through concentration changes, adjust dosage to balance hemostasis and thrombus risk.

. Surgery and trauma: Postoperative or post-traumatic monitoring to prevent secondary bleeding caused by fibrinolysis.

III. Scientific Analysis: Exploring the Relationship between Fibrinolytic Mechanisms and Diseases

The reagent kit provides standardized detection tools for scientific research, supporting the following studies:

Fibrinolytic System Regulation: studying the activation/inhibition pathways of fibrinogen, revealing the molecular mechanisms of thrombosis or bleeding.

. Development of disease biomarkers: Exploring the potential of fibrinogen as a biomarker for tumors, cardiovascular disease, or inflammation. Drug development: Evaluate the efficacy and safety of novel thrombolytic or anti fibrinolytic drugs.

Technical characteristics and advantages

Methodology: Adopting immune transmission turbidity method, double antibody sandwich method or enzyme-linked immunosorbent assay (ELISA), it has high sensitivity (detection range of 75pg/ml-2500pg/ml) and specificity.

. Sample type: Supports detection of multiple types of samples such as serum, plasma, tissue homogenate, and cell culture supernatant.

Easy to operate: Suitable for fully automatic analyzers (such as specific protein analyzers), enabling batch processing and reducing detection time (such as completing tests within 20 minutes).

.

Strict quality control: Non normal value quality control plasma is used to ensure that the coefficient of variation (CV) of the test results is ≤ 5%, which meets clinical laboratory standards.

.